A strategic corporate venture fund of a global pharmaceutical company actively invests in early-stage biotech companies that are of strategic interest to the parent pharmaceutical. The firm invests in global opportunities, but focuses primarily on North America and Europe.
The firm invests in early-stage therapeutics and platform technology companies. The firm’s main areas of interest include immunology and inflammation, kidney disease including transplant, serious diseases treated in hospitals, neurodegenerative disease, and rare disease. Regarding platform technologies, the firm is interested in drug discovery technologies for small molecule, peptide, nucleic acid, and other novel modalities, delivery systems (CNS, kidney disease), and cell therapies (excluding those targeting oncology). The firm invests primarily in pre-clinical opportunities, and can consider those as early as discovery stage. The firm does not actively seek opportunities in medical devices, diagnostics, or digital health at this time.
The firm has no specific company or management team requirements. The firm can help support companies beyond capital. The firm can offer scientific expertise, and is able to collaborate on early stage proof-of-concept experiments and projects with emerging companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment